ONCT Oncternal Therapeutics, Inc. Stock Quote

ONCT [NASD]

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	14.82%	Shs Outstand	49.28M	Perf Week	-1.20%
Market Cap	460.33M	Forward P/E	-	EPS next Y	-0.75	Insider Trans	0.00%	Shs Float	43.50M	Perf Month	43.15%
Income	-17.20M	PEG	-	EPS next Q	-0.10	Inst Own	21.70%	Short Float	0.49%	Perf Quarter	74.26%
Sales	3.40M	P/S	135.39	EPS this Y	74.40%	Inst Trans	114.48%	Short Ratio	0.12	Perf Half Y	366.67%
Book/sh	3.83	P/B	2.16	EPS next Y	-53.10%	ROA	-38.50%	Target Price	-	Perf Year	180.95%
Cash/sh	-	P/C	-	EPS next 5Y	0.00%	ROE	-46.40%	52W Range	1.49 - 10.56	Perf YTD	68.57%
Dividend	-	P/FCF	-	EPS past 5Y	8.60%	ROI	-15.50%	52W High	-21.78%	Beta	1.77
Dividend %	-	Quick Ratio	20.10	Sales past 5Y	-	Gross Margin	-	52W Low	454.36%	ATR	0.93
Employees	12	Current Ratio	20.10	Sales Q/Q	128.60%	Oper. Margin	-	RSI (14)	52.77	Volatility	12.90% 12.27%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	67.80%	Profit Margin	-	Rel Volume	1.65	Prev Close	9.34
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 11 AMC	Payout	-	Avg Volume	1.70M	Price	8.26
Recom	1.70	SMA20	-0.30%	SMA50	13.61%	SMA200	100.37%	Volume	2,795,351	Change	-11.56%

Apr-07-21

Initiated

Oppenheimer

Outperform

$14

Feb-23-21

Initiated

Northland Capital

Outperform

$21

Apr-08-21 04:04AM	Oncternal Therapeutics (ONCT) Soars 8.4%: Is Further Upside Left in the Stock? Zacks
Apr-05-21 08:34AM	Implied Volatility Surging for Oncternal Therapeutics (ONCT) Stock Options Zacks
Mar-18-21 04:38PM	Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.90%
Mar-15-21 06:12AM	We're Not Very Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate Simply Wall St. +13.87%
Mar-11-21 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire +10.40%
Mar-04-21 08:00AM	Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update GlobeNewswire -12.48%
Feb-24-21 08:00AM	Oncternal Therapeutics to Participate in March Investor Conferences GlobeNewswire
Feb-22-21 05:33PM	Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-28-21 04:01PM	Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors GlobeNewswire
Jan-14-21 08:00AM	Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program GlobeNewswire +11.59%
Jan-07-21 04:01PM	Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies GlobeNewswire
Jan-05-21 08:00AM	Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference GlobeNewswire
Dec-14-20 04:01PM	Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Dec-09-20 11:50PM	Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million GlobeNewswire +24.02%
06:08PM	Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering GlobeNewswire
Dec-07-20 08:00AM	Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting GlobeNewswire +49.62%
Nov-30-20 06:14PM	Is Oncternal Therapeutics (ONCT) A Good Stock To Buy Now? Insider Monkey
Nov-17-20 11:00PM	Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million GlobeNewswire -9.41%
05:28PM	Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering GlobeNewswire
Nov-11-20 08:00AM	Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting GlobeNewswire
Nov-10-20 10:51AM	Is Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Popular Amongst Insiders? Simply Wall St. +8.82%
Nov-09-20 04:01PM	Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference GlobeNewswire +30.10%
Nov-04-20 05:15PM	Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Oct-06-20 08:00AM	Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma Business Wire
Sep-22-20 07:00AM	Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments PR Newswire
Sep-21-20 08:00AM	Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020 Business Wire
Sep-10-20 08:00AM	Oncternal Therapeutics to Participate in September Investor Conferences Business Wire
Sep-03-20 08:29AM	The Independent Director of Oncternal Therapeutics, Inc. (NASDAQ:ONCT), Michael Carter, Just Bought 13,789% More Shares Simply Wall St.
Aug-27-20 09:18PM	Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 Million Business Wire
05:18PM	Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering Business Wire
Aug-06-20 04:15PM	Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results Business Wire
02:37PM	Oncternal Therapeutics'(NASDAQ:ONCT) Share Price Is Down 33% Over The Past Year. Simply Wall St.
Jul-30-20 08:00AM	Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update Business Wire -12.50%
Jul-27-20 08:00AM	Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma Business Wire
Jul-20-20 08:00AM	Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Business Wire
Jun-30-20 08:00AM	Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia Business Wire
07:45AM	Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma Business Wire
May-20-20 08:00AM	Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Business Wire
May-19-20 08:00AM	Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting Business Wire +23.17%
May-07-20 08:00AM	Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results Business Wire -5.87%
May-05-20 08:00AM	Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update Business Wire
May-01-20 08:00AM	Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update Business Wire
Mar-18-20 08:36AM	Is Oncternal Therapeutics (NASDAQ:ONCT) In A Good Position To Invest In Growth? Simply Wall St. -10.01%
Mar-16-20 04:05PM	Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results Business Wire
Mar-11-20 04:08PM	Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update Business Wire +12.20%
08:00AM	Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma Business Wire
Feb-06-20 08:00AM	Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Business Wire
Dec-12-19 06:00PM	Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium Business Wire
Dec-11-19 08:00AM	Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma Business Wire -10.62%
Dec-09-19 08:00AM	Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting Business Wire
Dec-03-19 08:00AM	Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium Business Wire
Nov-21-19 08:00AM	Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference Business Wire
Nov-14-19 04:02PM	Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting Business Wire
Nov-11-19 08:00AM	Oncternal Therapeutics to Present at Stifel Healthcare Conference Business Wire +5.74%
Nov-07-19 04:05PM	Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-05-19 08:00AM	Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting Business Wire +8.80%
Oct-31-19 08:00AM	Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update Business Wire
Oct-03-19 08:00AM	Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma Business Wire
Sep-20-19 12:03PM	We're Not Very Worried About Oncternal Therapeutics's (NASDAQ:ONCT) Cash Burn Rate Simply Wall St.
Sep-17-19 04:05PM	Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Childrens Oncology Group Meeting Business Wire -5.70%
Sep-09-19 08:00AM	Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer Business Wire
Aug-28-19 04:01PM	Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing Business Wire
Aug-08-19 04:01PM	Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-06-19 08:00AM	Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib GlobeNewswire +5.75%
Aug-01-19 04:01PM	Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update GlobeNewswire -5.29%
Jun-10-19 08:00AM	Oncternal Therapeutics Completes Reverse Merger with GTx, Inc. GlobeNewswire -16.31%

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CARTER MICHAEL G	Director	Sep 01	Buy	2.10	71,429	150,001	71,947	Sep 02 04:53 PM
AKER HAZEL M	Legal Counsel	Jul 21	Buy	2.38	41,972	99,998	46,987	Jul 23 05:00 PM
KISNER DANIEL L	Director	Jul 21	Buy	2.38	10,000	23,825	10,000	Jul 23 05:00 PM
Shanghai Pharmaceutical (USA)	10% Owner	Jul 21	Buy	2.38	1,049,317	2,499,998	3,544,431	Jul 23 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience